FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310107585> ?p ?o ?g. }

• W4310107585 endingPage "2100" @default.
• W4310107585 startingPage "2098" @default.
• W4310107585 abstract "Introduction: GEM2014MAIN is a phase 3, multicenter, open-label, randomized trial exploring maintenance treatment with lenalidomide and dexamethasone (Rd) vs lenalidomide, dexamethasone and ixazomib (IRd) after autologous stem cell transplantation in newly diagnosed patients with multiple myeloma (MM). The study includes yearly analysis of minimal residual disease (MRD) in bone marrow (BM) by Next Generation Flow (NGF) and the results at year 2 guide further management. Mass spectrometry methods measuring low-level immunoglobulins have shown potential for peripheral-blood (PB) based MRD assessment in MM. Aim: In this study, we analyzed and compared the results and clinical impact of MRD evaluation in BM by NGF and in PB by quantitative immunoprecipitation mass-spectrometry (QIP-MS) during maintenance in patients enrolled in the GEM2014MAIN trial. Patients and Methods: Patients achieving at least stable disease at the end of the GEM2012MENOS65 trial were included in the GEM14MAIN, and randomized to receive Rd (lenalidomide 15mg po od days 1-21 and dexamethasone 20mg po od days 1-4 and 9-12) or IRd (Rd plus ixazomib 4mg po od days 1, 8 and 15) in cycles of 28 days. After two years of treatment, BM samples were analyzed by NGF (sensitivity of 3x10-6) as per protocol: if MRD was undetectable, maintenance was discontinued; if detectable, Rd with reduced dexamethasone at 20mg po od only days 1-4 was continued for 3 additional years. At the same time point, MRD was assessed in PB by QIP-MS with anti IgG/A/M, total k and total l beads using the EXENT system (The Binding Site, in development). The association of MRD detection by either method with progression-free survival (PFS) was assessed by the Kaplan-Meier method. Landmark analyses of PFS at 2 years post-maintenance were performed to minimize lead-time bias. Additional survival analyses were carried out to evaluate the clinical impact of MRD evolution during the study period. Results: 156 patients with paired BM/PB samples available after 2 years of maintenance were included in the analysis. NGF detected residual disease in 29% (45/156) of cases and EXENT in 24% (37/156). The results of both techniques were concordant in 85% of cases and discordances were due to 16 patients (10%) NGF+/EXENT- and 8 (5%) NGF-/EXENT+. Of note, 8/16 cases NGF+/EXENT- corresponded to light-chain MM (anti-free light chain beads were not used in this study). Therefore, overall, and considering NGF as a reference, the negative predictive value (NPV) of EXENT was 87% and the positive predictive value (PPV) of 78% (p<0.0001). With a median follow-up of 66 months from the start of the GEM14MAIN, MRD detection by either method associated with a shorter PFS at 5 years as compared to patients with undetectable MRD: NGF: 57% vs 89%, respectively; HR= 6.54 (2.92-14.67); p<0.0001; EXENT: 62%% vs 86%, respectively; HR= 4.79 (1.99-11.53); p=0.0005. We also analyzed the evolution of MRD between enrollment and after 2 years of maintenance, since we already had MRD results by both methods at the end of the GEM2012. Patients were grouped into 1) those with persistent MRD positivity at the two time points or converting from MRD- to + by either method and 2) those with sustained MRD negativity at the two time points or converting from MRD+ to - by either method. Both NGF and EXENT showed that persistent MRD+ or conversion from MRD- to MRD+ were associated with a shorter PFS at 66 months, compared to patients who remained MRD- or converted from MRD+ to MRD-: NGF: 54% vs 89%, respectively; HR = 8.9 (3.55-22.08); p <0.0001; EXENT: 61% vs 86%, respectively; HR: 4.95 (1.91-12.9); p=0.0010. Conclusions: Our study shows that, during maintenance, the identification of MRD by NGF and EXENT and its evolutionary pattern are both associated with a comparable clinical value in terms of PFS. Supported by a NPV of 87% as compared to NGF, mass spectrometry could be used to define the optimal time-point for BM-based MRD assessments as well as, alongside with standard methods, to introduce MRD adapted treatment approaches." @default.
• W4310107585 created "2022-11-30" @default.
• W4310107585 creator A5006758299 @default.
• W4310107585 creator A5013916379 @default.
• W4310107585 creator A5016479494 @default.
• W4310107585 creator A5020420490 @default.
• W4310107585 creator A5029159537 @default.
• W4310107585 creator A5029958963 @default.
• W4310107585 creator A5032722606 @default.
• W4310107585 creator A5035866456 @default.
• W4310107585 creator A5047672322 @default.
• W4310107585 creator A5047827455 @default.
• W4310107585 creator A5054952877 @default.
• W4310107585 creator A5056575626 @default.
• W4310107585 creator A5056987348 @default.
• W4310107585 creator A5057189669 @default.
• W4310107585 creator A5059482051 @default.
• W4310107585 creator A5060669113 @default.
• W4310107585 creator A5060774512 @default.
• W4310107585 creator A5064147442 @default.
• W4310107585 creator A5064150483 @default.
• W4310107585 creator A5066234242 @default.
• W4310107585 creator A5071364391 @default.
• W4310107585 creator A5077430940 @default.
• W4310107585 creator A5089163384 @default.
• W4310107585 creator A5089409240 @default.
• W4310107585 date "2022-11-15" @default.
• W4310107585 modified "2023-10-18" @default.
• W4310107585 title "Clinical Impact of Next Generation Flow in Bone Marrow <i>Vs</i> Qip-Mass Spectrometry in Peripheral Blood to Assess Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients Receiving Maintenance As Part of the GEM2014MAIN Trial" @default.
• W4310107585 doi "https://doi.org/10.1182/blood-2022-165441" @default.
• W4310107585 hasPublicationYear "2022" @default.
• W4310107585 type Work @default.
• W4310107585 citedByCount "2" @default.
• W4310107585 countsByYear W43101075852023 @default.
• W4310107585 crossrefType "journal-article" @default.
• W4310107585 hasAuthorship W4310107585A5006758299 @default.
• W4310107585 hasAuthorship W4310107585A5013916379 @default.
• W4310107585 hasAuthorship W4310107585A5016479494 @default.
• W4310107585 hasAuthorship W4310107585A5020420490 @default.
• W4310107585 hasAuthorship W4310107585A5029159537 @default.
• W4310107585 hasAuthorship W4310107585A5029958963 @default.
• W4310107585 hasAuthorship W4310107585A5032722606 @default.
• W4310107585 hasAuthorship W4310107585A5035866456 @default.
• W4310107585 hasAuthorship W4310107585A5047672322 @default.
• W4310107585 hasAuthorship W4310107585A5047827455 @default.
• W4310107585 hasAuthorship W4310107585A5054952877 @default.
• W4310107585 hasAuthorship W4310107585A5056575626 @default.
• W4310107585 hasAuthorship W4310107585A5056987348 @default.
• W4310107585 hasAuthorship W4310107585A5057189669 @default.
• W4310107585 hasAuthorship W4310107585A5059482051 @default.
• W4310107585 hasAuthorship W4310107585A5060669113 @default.
• W4310107585 hasAuthorship W4310107585A5060774512 @default.
• W4310107585 hasAuthorship W4310107585A5064147442 @default.
• W4310107585 hasAuthorship W4310107585A5064150483 @default.
• W4310107585 hasAuthorship W4310107585A5066234242 @default.
• W4310107585 hasAuthorship W4310107585A5071364391 @default.
• W4310107585 hasAuthorship W4310107585A5077430940 @default.
• W4310107585 hasAuthorship W4310107585A5089163384 @default.
• W4310107585 hasAuthorship W4310107585A5089409240 @default.
• W4310107585 hasBestOaLocation W43101075851 @default.
• W4310107585 hasConcept C126322002 @default.
• W4310107585 hasConcept C2776364478 @default.
• W4310107585 hasConcept C2779823535 @default.
• W4310107585 hasConcept C2780007613 @default.
• W4310107585 hasConcept C71924100 @default.
• W4310107585 hasConceptScore W4310107585C126322002 @default.
• W4310107585 hasConceptScore W4310107585C2776364478 @default.
• W4310107585 hasConceptScore W4310107585C2779823535 @default.
• W4310107585 hasConceptScore W4310107585C2780007613 @default.
• W4310107585 hasConceptScore W4310107585C71924100 @default.
• W4310107585 hasIssue "Supplement 1" @default.
• W4310107585 hasLocation W43101075851 @default.
• W4310107585 hasOpenAccess W4310107585 @default.
• W4310107585 hasPrimaryLocation W43101075851 @default.
• W4310107585 hasRelatedWork W2023790312 @default.
• W4310107585 hasRelatedWork W2064513556 @default.
• W4310107585 hasRelatedWork W2351838294 @default.
• W4310107585 hasRelatedWork W2754408221 @default.
• W4310107585 hasRelatedWork W2895640407 @default.
• W4310107585 hasRelatedWork W2989947979 @default.
• W4310107585 hasRelatedWork W3005134712 @default.
• W4310107585 hasRelatedWork W3210305293 @default.
• W4310107585 hasRelatedWork W4303685439 @default.
• W4310107585 hasRelatedWork W4307728285 @default.
• W4310107585 hasVolume "140" @default.
• W4310107585 isParatext "false" @default.
• W4310107585 isRetracted "false" @default.
• W4310107585 workType "article" @default.